프론트바이오 - 로고

Anti-cancer Drug

  • R&D
  • Anti-cancer Drug

Discovering novel anticancer drugs
with new action mechanism

  • Medical Unmet Need

    • No safe anticancer drugs without side effects
    • Difficulty in administering due to injection
  • Problems of current treatments

    • 1st-generation chemical anticancer drugs :
      damages in normal tissues, vomiting, pain, and side effects such as hair loss and sperm death
    • 2nd-generation target anticancer drug : low target efficiency and developing resistance to treatment
    • 3rd-generation immune anticancer drug : low response rate of drugs, inevitable co-treatment with chemical anticancer drugs

Discovering novel anticancer drugs
with new action mechanism

  • Action Mechanism

    A combination of existing drugs
    (2 or 3 types) currently used for other indications

    • FB300-A

      Produces the apoptosis-inducing substance only in cancer cells

    • FB300-B (1 or 2)

      Amplifies the apoptosis-inducing substance and results in apoptosis of cancer cells

    • 1) Anticancer drug with new action mechanism
    • 2) New anticancer drug with no side effect due to no influence to normal cells
    • 3) Easy treatment via oral administration
    • 4) Secured safety for preclinical and clinical trials because of a combination of existing proven drugs
    • 5) Acquisition of exclusive rights by completing patent registration

Action Mechanism of New Anticancer Drug:
Amplification of apoptosis-inducing substance only in cancer cell

Anticancer action mechanism
of FB300 series

Apoptosis-inducing substance is amplified when FB300A and FB30B are treated in combination.

  • AsPC-1
    (Pancreas
    cancer cells)

    Treated alone
    (A or B)

  • AsPC-1
    (Pancreatic
    cancer cells)

    Treated in combination
    (A+B)

  • Intensity
  • Intensity

Anticancer activity of FB300
(in cancer cells)

  • Cell
  • Animal

Synergistic anticancer activity
of FB300 (A+B)
for various cancer cells
when treated in combination.

  • HCC-1195

    Lung cancer

  • HCT-116

    Colon cancer

  • DU145

    Prostate cancer

  • ASPC1

    Pancreas cancer

AsPC-1


Pancreas cancer

  • Control : tumor

  • A + B (125 +10) : tumor

Excellent anticancer activity
of FB300 in a nude mouse
xenograft model
of pancreas cancer cells (AsPC-1)

Competitiveness of FB300 series

New anticancer drug
FB300
series

  • Specialty

    New MoA

    New action mechanism

    A combination of existing
    drugs (2 or 3)

    Secured safety and
    advantageous to FDA approval

    Oral anticancer drugs

    Convenient administration

    No Side effects

    No vomit, pain, and hair loss

    Excellent efficacy for
    various cancer types

    Anticancer activity in pancreatic
    and brain cancers

  • Marketability

    Big Market Size

    Current: 150 billion $
    2022: 200 billion $ expected

  • Monopoly

    Secured intellectual
    property rights

    Completed domestic patent
    registration Overseas PCT
    on application